Oncogenic B-RafV600E abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells

Cancer Letters

Volumn 337, Issue 1, 2013, Pages 125-132

  Zhang, Ling ^a   Shi, Ruyi ^a   He, Chanting ^a   Cheng, Caixia ^a   Song, Bin ^a   Cui, Heyang ^a   Zhang, Yanyan ^a   Zhao, Zhiping ^a   Bi, Yanghui ^a   Yang, Xiaofeng ^a   Miao, Xiaoping ^b   Guo, Jiansheng ^a   Chen, Xing ^c   Wang, Jinfen ^d   Li, Yaoping ^d   Cheng, Xiaolong ^a   Liu, Jing ^a   Cui, Yongping ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^d SHANXI CANCER HOSPITAL   (China)

Author keywords

AKT; B Raf ERK signaling; B RafV600E; Melanoma; Mps1; Negative feedback

Indexed keywords

B RAF KINASE; MPS1 PROTEIN; PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; AUTOREGULATION; B RAF GENE; CARCINOGENESIS; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA CELL; NEGATIVE FEEDBACK; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

AKT; B-RAF(V600E); B-RAF/ERK SIGNALING; MELANOMA; MPS1; NEGATIVE FEEDBACK;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEEDBACK, PHYSIOLOGICAL; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MUTATION; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84880042990     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.029     Document Type: Article

References (34)

1. Romeo Y., Moreau J., Zindy P.J., Saba-El-Leil M., Lavoie G., Dandachi F., Baptissart M., Borden K.L., Meloche S., Roux P.P. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth. Oncogene 2012, http://dx.doi.org/10.1038/onc.2012.312.
2. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Cancer genome project. Mechanism of activation of the RAF-MAPK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
3. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
4. Dhomen N., Reis-Filho J.S., da Rocha D.S., Hayward R., Savage K., Delmas V., Larue L., Pritchard C., Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009, 15:294-303.
5. Hooijkaas A.I., Gadiot J., van der Valk M., Mooi W.J., Blank C.U. Targeting BRAF(V600E) in an inducible murine model of melanoma. Am. J. Pathol. 2012, http://dx.doi.org/10.1016/j.ajpath.2012.06.002.
6. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
7. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., Burton E.A., Wong B., Tsang G., West B.L., Powell B., Shellooe R., Marimuthu A., Nguyen H., Zhang K.Y., Artis D.R., Schlessinger J., Su F., Higgins B., Iyer R., D'Andrea K., Koehler A., Stumm M., Lin P.S., Lee R.J., Grippo J., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., Chapman P.B., Flaherty K.T., Xu X., Nathanson K.L., Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
8. Fisk H.A., Mattison C.P., Winey M. Human Mps1 protein kinase is required for centrosome duplication and normal mitotic progression. Proc. Natl. Acad. Sci. USA 2003, 100:14875-14880.
9. Cui Y., Guadagno T.M. B-RafV600E signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. Oncogene 2008, 27:3122-3133.
10. Cui Y., Borysova M.K., Johnson J.O., Guadagno T.M. Oncogenic B-RafV600E induces spindle abnormalities, supernumerary centrosomes, an aneuploidy in human melanocytic cells. Cancer Res. 2010, 70:675-684.
11. Jing Liu, Xiaolong Cheng, Yanyan Zhang, Shujing Li, Heyang Cui, Ling Zhang, Ruyi Shi, Zhiping Zhao, Chanting He, Chuangui Wang, Haoliang Zhao, Ce Zhang, Fisk Harold A., Guadagno Thomas M., Cui Yongping Phosphorylation of Mps1 by BRAFV600E prevents Mps1 degradation and contributes to chromosome instability in melanoma. Oncogene 2012, http://dx.doi.org/10.1038/onc.2012.94.
12. Chadee D.N., Kyriakis J.M. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat. Cell Biol. 2004, 6:770-776.
13. Borysova M.K., Cui Y., Snyder M., Guadagno T.M. Knockdown of B-Raf impairs spindle formation and the mitotic checkpoint in human somatic cells. Cell Cycle 2008, 7(18):2894-2901.
14. Cui Y., Cheng X., Zhang C., Zhang Y., Li S., Wang C., Guadagno T.M. Degradation of the human mitotic checkpoint kinase Mps1 is cell-cycle regulated by APC/cCdc20 and APC/cCdh1 ubiquitin ligases. J. Biol. Chem. 2010, 285(43):32988-32998.
15. Kasbek C., Yang C.H., Fisk H.A. Antizyme restrains centrosome amplification by regulating the accumulation of mps1 at centrosomes. Mol. Biol. Cell 2010, 21:3878-3889.
16. Jelluma N., Brenkman A.B., van den Broek N.J., Cruijsen C.W., van Osch M.H., Lens S.M., Medema R.H., Kops G.J. Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment. Cell 2008, 132(2):233-246.
17. Althoff F., Karess R.E., Lehner C.F. Spindle checkpoint-independent inhibition of mitotic chromosome segregation by Drosophila Mps1. Mol. Biol. Cell 2012, 23(12):2275-2291.
18. Fisk H.A., Winey M. The mouse mps1p-like kinase regulates centrosome duplication. Cell 2001, 106:95-104.
19. Buck E., Eyzaguirre A., Rosenfeld-Franklin M., Thomson S., Mulvihill M., Barr S., Brown E., O'Connor M., Yao Y., Pachter J., Miglarese M., Epstein D., Iwata K.K., Haley J.D., Gibson N.W., Ji Q.S. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008, 68(20):8322-8332.
20. Mirzoeva O.K., Das D., Heiser L.M., Bhattacharya S., Siwak D., Gendelman R., Bayani N., Wang N.J., Neve R.M., Guan Y., Hu Z., Knight Z., Feiler H.S., Gascard P., Parvin B., Spellman P.T., Shokat K.M., Wyrobek A.J., Bissell M.J., McCormick F., Kuo W.L., Mills G.B., Gray J.W., Korn W.M. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009, 69(2):565-572.
21. Stucke V.M., Sillje H.H., Arnaud L., Nigg E.A. Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication. Embo J. 2002, 21:1723-1732.
22. Yamagishi Y., Yang C.H., Tanno Y., Watanabe Y. MPS1/Mph1 phosphorylates the kinetochore protein KNL1/Spc7 to recruit SAC components. Nat. Cell Biol. 2012, 14(7):746-752.
23. Janssen A., Kops G.J., Medema R.H. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc. Natl. Acad. Sci. USA 2009, 106(45):19108-19113.
24. Kasbek C., Yang C.H., Fisk H.A. Mps1 as a link between centrosomes instability. Environ. Mol. Mutagen. 2009, 50:654-665.
25. Hogg D., Guidos C., Bailey D., Amendola A., Groves T., Davidson J., Schmandt R., Mills G. Cell cycle dependent regulation of the protein kinase TTK. Oncogene 1994, 9:89-96.
26. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H., Kaempgen E., Martín-Algarra S., Karaszewska B., Mauch C., Chiarion-Sileni V., Martin A.M., Swann S., Haney P., Mirakhur B., Guckert M.E., Goodman V., Chapman P.B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, http://dx.doi.org/10.1016/S0140-6736(12)60868-X.
27. Koya R.C., Mok S., Otte N., Blacketor K.J., Comin-Anduix B., Tumeh P.C., Minasyan A., Graham N., Graeber T.G., Chodon T., Ribas A. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012, http://dx.doi.org/10.1158/0008-5472.CAN-11-2837.
28. Margolin K. BRAF inhibition and beyond in advanced melanoma. Lancet 2012, http://dx.doi.org/10.1016/S0140-6736(12)60993-3.
29. Diaz L.A., Williams R.T., Wu J., Kinde I., Hecht J.R., Berlin J., Allen B., Bozic I., Reiter J.G., Nowak M.A., Kinzler K.W., Oliner K.S., Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486(7404):537-540.
30. Zhao Y., Chen R.H. Mps1 phosphorylation by MAP kinase is required for kinetochore localization of spindle-checkpoint proteins. Curr. Biol. 2006, 16:1764-1769.
31. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., Salem G., Pohida T., Heenan P., Duray P., Kallioniemi O., Hayward N.K., Trent J.M., Meltzer P.S. High frequency of BRAF mutation in nevi. Nat. Genet. 2003, 33(1):19-20.
32. Chen Brenden, Tardell Christine, Higgins Brian, Packman Kathryn, Boylan John F., Niu Huifeng BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One 2012, 7(8):e42598.
33. Maddodi N., Huang W., Havighurst T., Kim K., Longley B.J., Setaluri V. Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J. Invest. Dermatol. 2010, 130(6):1657-1667.
34. Zheng B., Jeong J.H., Asara J.M., Yuan Y.Y., Granter S.R., Chin L., Cantley L.C. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 2009, 33(2):237-247.